undamentalytics Newsletter
Sign in

Bridgebio Pharma, Inc. cash flow statement

In fiscal 2025, Bridgebio Pharma, Inc.'s operations generated −$446m of cash; it spent $1.1m on capital projects, leaving free cash flow of −$447m. It returned $48.3m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−254−400−498−419−528−521−446−369
Depreciation and amortisation11676655
Stock-based pay21581009210996133152
Capital spending381351111
Free cash flow−256−407−511−424−529−522−447−370
Free cash flow after stock pay−278−466−611−516−638−617−580−522
Dividends paid1———————
Share buybacks—7520000048253
Shares issued—0054503150—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BBIO vs KNSABBIO vs BCRXBBIO vs IONSBBIO vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bridgebio Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bridgebio Pharma, Inc.